Basel-based CDMO Start-up Focuses on Injectables
Open for business since August, the company operates from the Rosental campus in Basel on 4,000 m2 of workspace, including a fully operational lab and office building taken over from Elanco. With the acquisition of new clients and projects, the startup plans to eventually provide a work environment for 150 full-time employees in addition to others working remotely. Currently, it has a staff of 20, including some former Elanco employees.
Mahler, a German national who formerly headed Drug Product Services at Lonza, with previous roles as head of Pharmaceutical Development & Supplies at Roche and principal scientist at Merck, functions as the company’s CEO, an acronym for what it calls Chief Enabling Officer.
“There is a significant unmet need in the life sciences market,” Mahler noted in announcing the launch. “The number and complexity of molecules and novel therapeutic modalities are increasing, and medical research is facing growing challenges with respect to the stability, usability, and consistent manufacturing of medicines.”
According to the CEO and founder, the young company’s “comprehensive offering,” which will include formulation development, drug product development and manufacturing as well as testing services for sterile pharmaceutical products, will allow its clients to focus on the medicine and the patient, while leveraging the CDMO’s pharmaceutical expertise and knowledge to plan and de-risk product development. At the same time, Ten23 Health “will enable commercialization “with speed, quality, and success.” The company’s partners, Mahler added, “will benefit from shorter development timelines, a higher probability of technical success and ultimately stronger market positioning.”
Richard Relyea, partner at 3i and a member of the start-up’s board of directors, said the private equity group’s investment is aimed at supporting the establishment of a “uniquely differentiated partner” to leading global biotech and pharmaceutical customers in the development, manufacturing and testing of complex and effective injectable biopharmaceutical drugs.
One differentiating factor will surely be that Ten23 Health intends to aim for net zero emissions and will track employees’ personal footprint, recognizing those who reduce their carbon usage.
Author: Dede Williams, Freelance Journalist
-
A new CDMO known as Ten23 Health has been launched in Basel, Switzerland. The company that takes its name from Avogadro’s number, a proportion that relates molar mass on an atomic scale to physical mass on a human scale, was founded by Hanns-Christian Mahler, a former employee of several well-known industry players, and is financed by 3i Group of London. (c) Ten23 Health
